Viridian Therapeutics, Inc.\DE (VRDN) Research & Development: 2014-2025
Historic Research & Development for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $86.3 million.
- Viridian Therapeutics, Inc.\DE's Research & Development rose 24.73% to $86.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.7 million, marking a year-over-year increase of 57.03%. This contributed to the annual value of $238.3 million for FY2024, which is 49.13% up from last year.
- According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Research & Development is $86.3 million, which was down 0.42% from $86.6 million recorded in Q2 2025.
- Viridian Therapeutics, Inc.\DE's Research & Development's 5-year high stood at $86.6 million during Q2 2025, with a 5-year trough of $8.1 million in Q3 2021.
- For the 3-year period, Viridian Therapeutics, Inc.\DE's Research & Development averaged around $58.9 million, with its median value being $56.2 million (2024).
- Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 227.55% in 2021, then fell by 19.31% in 2024.
- Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Research & Development stood at $22.4 million in 2021, then spiked by 75.57% to $39.3 million in 2022, then dropped by 1.93% to $38.6 million in 2023, then skyrocketed by 86.63% to $72.0 million in 2024, then rose by 24.73% to $86.3 million in 2025.
- Its Research & Development was $86.3 million in Q3 2025, compared to $86.6 million in Q2 2025 and $76.8 million in Q1 2025.